Keppra

Levetiracetam, the active ingredient in Keppra, is a pyrrolidine derivative presented as an injectable solution for intravenous use. It belongs to the antiepileptic therapeutic class and is used to treat partial‑onset, myoclonic, and primary generalized tonic‑clonic seizures in patients with epilepsy.

GNH USA supplies Keppra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets. The company adheres to EU Good Manufacturing Practice and provides reliable logistics for global distribution.

Levetiracetam is an antiepileptic medication that reduces abnormal neuronal firing in the brain.

- Partial‑onset seizures: decreases frequency and severity of focal seizure episodes. - Myoclonic seizures: reduces the occurrence of sudden muscle jerks. - Primary generalized tonic‑clonic seizures: helps prevent full‑body convulsive seizures.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue: feeling unusually tired or weak. - Dizziness: light‑headed sensation or loss of balance. - Somnolence: increased sleepiness during the day. - Headache: mild to moderate cranial pain. - Irritability: mood changes or increased agitation. - Nausea: upset stomach or urge to vomit.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: serious skin blistering condition. - Suicidal thoughts: new or worsening depression or suicidal ideation. - Severe depression: marked mood disturbances requiring medical attention. - Blood dyscrasias: rare cases of low blood cell counts. - Respiratory depression: difficulty breathing in rare cases.

When using levetiracetam, certain precautions should be observed to ensure safety and optimal therapy.

- Renal impairment: assess kidney function and adjust therapy as needed. - Pregnancy: category B; use only if potential benefit justifies potential risk. - Psychiatric symptoms: monitor for mood changes, depression, or suicidal ideation. - Hepatic function: evaluate liver enzymes periodically. - Concomitant CNS depressants: use with caution due to additive sedation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin, phenobarbital): may lower levetiracetam plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin): can reduce drug exposure. - Ritonavir: may increase levetiracetam concentrations leading to toxicity. - Other CNS depressants (e.g., opioids, benzodiazepines): risk of excessive sedation. - Alcohol: can potentiate central nervous system effects.

Moderate Interactions (Monitor Closely): - Valproate: may increase levetiracetam levels; monitor clinical response. - Lamotrigine: combined use may heighten skin rash risk. - NSAIDs: possible increase in adverse CNS effects. - Antidepressants (e.g., SSRIs): watch for mood alterations. - Oral contraceptives: may slightly reduce levetiracetam efficacy; monitor seizure control.